pharmaphorum
MAY 9, 2022
SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually.
pharmaphorum
APRIL 25, 2022
Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . Gani started BehaVR in 2016 to create DTx for mental and behavioural health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 27, 2022
Immersive technology can also help improve assessments of the effectiveness of treatment, particularly regarding behavioural health where a patient’s results are often subjective. Self-reporting can put patients in an awkward spot to adequately describe their feelings or thoughts, and this method can sometimes be unreliable.
pharmaphorum
JANUARY 26, 2021
There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. We’re starting to see this happen through the emergence of smart homes and smart cars (i.e.,
pharmaphorum
MARCH 21, 2022
In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder. About the author .
Expert insights. Personalized for you.
134 
Let's personalize your content